Compare Anheuser-Busch Inbev SA (BUD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Citius Pharmaceuticals Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.34 (market cap $159.01B), while Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M). The key difference: Anheuser-Busch Inbev SA is far larger — about 7946.5× Citius Pharmaceuticals Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BUD | CTXR | |
|---|---|---|
Market Cap | $159.01B | $20.01M |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $1.82 |
52-Week Low | $57.93 | $0.48 |
Enterprise Value | $223.42B | $16.23M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.
The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
